CURIS INC (CRIS) Stock Fundamental Analysis
NASDAQ:CRIS - Nasdaq - US2312693094 - Common Stock - Currency: USD
CRIS gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 551 industry peers in the Biotechnology industry. Both the profitability and financial health of CRIS have multiple concerns. CRIS is valied quite expensively at the moment, while it does show a decent growth rate.
1. Profitability
1.1 Basic Checks
CRIS had negative earnings in the past year.
CRIS had a negative operating cash flow in the past year.
CRIS had negative earnings in each of the past 5 years.
CRIS had a negative operating cash flow in each of the past 5 years.
1.2 Ratios
With a Return On Assets value of -107.13%, CRIS is not doing good in the industry: 77.50% of the companies in the same industry are doing better.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -107.13% | ||
| ROE | N/A | ||
| ROIC | N/A |
ROA(3y)-72.86%
ROA(5y)-52.24%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
CRIS has a better Gross Margin (99.42%) than 98.91% of its industry peers.
CRIS's Gross Margin has been stable in the last couple of years.
The Profit Margin and Operating Margin are not available for CRIS so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 99.42% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y1.41%
GM growth 5Y0.85%
2. Health
2.1 Basic Checks
CRIS does not have a ROIC to compare to the WACC, probably because it is not profitable.
CRIS has more shares outstanding than it did 1 year ago.
CRIS has more shares outstanding than it did 5 years ago.
CRIS has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
2.2 Solvency
CRIS has an Altman-Z score of -47.36. This is a bad value and indicates that CRIS is not financially healthy and even has some risk of bankruptcy.
CRIS has a Altman-Z score of -47.36. This is amonst the worse of the industry: CRIS underperforms 92.20% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | N/A | ||
| Debt/FCF | N/A | ||
| Altman-Z | -47.36 |
ROIC/WACCN/A
WACC11.02%
2.3 Liquidity
A Current Ratio of 1.23 indicates that CRIS should not have too much problems paying its short term obligations.
CRIS has a worse Current ratio (1.23) than 85.30% of its industry peers.
CRIS has a Quick Ratio of 1.23. This is a normal value and indicates that CRIS is financially healthy and should not expect problems in meeting its short term obligations.
CRIS's Quick ratio of 1.23 is on the low side compared to the rest of the industry. CRIS is outperformed by 84.57% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.23 | ||
| Quick Ratio | 1.23 |
3. Growth
3.1 Past
CRIS shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 27.64%, which is quite impressive.
CRIS shows quite a strong growth in Revenue. In the last year, the Revenue has grown by 14.17%.
CRIS shows a small growth in Revenue. Measured over the last years, the Revenue has been growing by 1.75% yearly.
EPS 1Y (TTM)27.64%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%39.02%
Revenue 1Y (TTM)14.17%
Revenue growth 3Y0.8%
Revenue growth 5Y1.75%
Sales Q2Q%14.09%
3.2 Future
The Earnings Per Share is expected to grow by 14.11% on average over the next years. This is quite good.
CRIS is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 58.60% yearly.
EPS Next Y45.45%
EPS Next 2Y29.39%
EPS Next 3Y21.27%
EPS Next 5Y14.11%
Revenue Next Year10.45%
Revenue Next 2Y9.98%
Revenue Next 3Y37.68%
Revenue Next 5Y58.6%
3.3 Evolution
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
4. Valuation
4.1 Price/Earnings Ratio
CRIS reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for CRIS. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
A more expensive valuation may be justified as CRIS's earnings are expected to grow with 21.27% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y29.39%
EPS Next 3Y21.27%
5. Dividend
5.1 Amount
No dividends for CRIS!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
NASDAQ:CRIS (8/7/2025, 8:18:47 PM)
1.715
+0.05 (+2.69%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners44.65%
Inst Owner Change0%
Ins Owners8.63%
Ins Owner Change0%
Market Cap20.58M
Analysts81.82
Price Target16.66 (871.43%)
Short Float %1.86%
Short Ratio1.73
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)3.35%
Min EPS beat(2)-3.2%
Max EPS beat(2)9.89%
EPS beat(4)1
Avg EPS beat(4)-13.67%
Min EPS beat(4)-42.45%
Max EPS beat(4)9.89%
EPS beat(8)5
Avg EPS beat(8)-4.13%
EPS beat(12)7
Avg EPS beat(12)-1.64%
EPS beat(16)8
Avg EPS beat(16)-2.72%
Revenue beat(2)1
Avg Revenue beat(2)25.31%
Min Revenue beat(2)-10.12%
Max Revenue beat(2)60.74%
Revenue beat(4)3
Avg Revenue beat(4)24.44%
Min Revenue beat(4)-10.12%
Max Revenue beat(4)60.74%
Revenue beat(8)4
Avg Revenue beat(8)8.34%
Revenue beat(12)4
Avg Revenue beat(12)2.25%
Revenue beat(16)6
Avg Revenue beat(16)1.03%
PT rev (1m)0%
PT rev (3m)2.08%
EPS NQ rev (1m)34.56%
EPS NQ rev (3m)-4.95%
EPS NY rev (1m)-22.08%
EPS NY rev (3m)-20.9%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0.15%
Revenue NY rev (1m)1.05%
Revenue NY rev (3m)-4.82%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | 1.84 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | N/A | ||
| P/tB | N/A | ||
| EV/EBITDA | N/A |
EPS(TTM)-6.23
EYN/A
EPS(NY)-2.29
Fwd EYN/A
FCF(TTM)-2.8
FCFYN/A
OCF(TTM)-2.8
OCFYN/A
SpS0.93
BVpS-0.55
TBVpS-1.3
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -107.13% | ||
| ROE | N/A | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 99.42% | ||
| FCFM | N/A |
ROA(3y)-72.86%
ROA(5y)-52.24%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y1.41%
GM growth 5Y0.85%
F-Score4
Asset Turnover0.28
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | N/A | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | N/A | ||
| Cap/Sales | N/A | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 1.23 | ||
| Quick Ratio | 1.23 | ||
| Altman-Z | -47.36 |
F-Score4
WACC11.02%
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)27.64%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%39.02%
EPS Next Y45.45%
EPS Next 2Y29.39%
EPS Next 3Y21.27%
EPS Next 5Y14.11%
Revenue 1Y (TTM)14.17%
Revenue growth 3Y0.8%
Revenue growth 5Y1.75%
Sales Q2Q%14.09%
Revenue Next Year10.45%
Revenue Next 2Y9.98%
Revenue Next 3Y37.68%
Revenue Next 5Y58.6%
EBIT growth 1Y14.13%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year12%
EBIT Next 3Y-18.99%
EBIT Next 5Y1.48%
FCF growth 1Y33.01%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y32.46%
OCF growth 3YN/A
OCF growth 5YN/A